FDA panel votes against Capricor's Duchenne heart disease therapy - Reuters
FDA panel votes against Capricor's Duchenne heart disease therapy Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOak9HZVhUZnY3QmJXSGtDZ0JCdlZ5Q3dWLU9ZYzAyV2pEWFBkREI2aTU5ZnliYkFJay1HNElhbWltSlZBNUtqMFVqMi0wMkdwU0tKQlRYS3NKRDEtd2xXTGFDRkxvaHVYWHFuMFlmVS0zRGNZRXlZRzNOM3llc2NudmNBTFRkcFhNblVxZldJQjNwaUVqLTdESE82WFkyMUJFZzltVENWUlpVcEhOZ0NjaXB1dWFjeWpPUml5YnVRSzROUTFOcVBzTnpBWU5HVEJkbGc?oc=5" target="_blank">FDA panel votes against Capricor's Duchenne heart disease therapy</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
'What terminal cancer has taught me about life'
A Gloucestershire man with terminal cancer shares the life lessons he wishes he'd learned sooner.
October 10, 2026 at 06:16 AMUS FDA approves Asahi Kasei's drug for persistent herpes infections - Reuters
US FDA approves Asahi Kasei's drug for persistent herpes infections Reuters
October 9, 2026 at 06:01 PMTeva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Teva wins FDA approval for monthly schizophrenia injection Weltruza Reuters
October 9, 2026 at 11:47 AMUS FDA flags four deaths in Newron's schizophrenia drug studies - Reuters
US FDA flags four deaths in Newron's schizophrenia drug studies Reuters
October 8, 2026 at 05:47 PMUS FDA expands use of Novartis drug for chronic skin condition - Reuters
US FDA expands use of Novartis drug for chronic skin condition Reuters
October 7, 2026 at 04:51 PMAlector soars as Roche licenses Parkinson's therapy for up to $1.27 billion - Reuters
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion Reuters
October 5, 2026 at 12:15 PM